Choosing a CDMO Partner for Your Late-Stage and Commercial Biologics Programs

Summary: Choosing a CDMO Partner for Your Late-Stage and Commercial Biologics Programs (A fireside chat with Catalent’s expert).
There are many requirements for choosing a CDMO for your late-stage and commercial biologics programs, including strong regulatory expertise, commercial launch experience, smooth tech transfer and process characterizations, among other factors. Different types of programs will have unique needs depending on the therapeutic modalities, specific indication, and program types. Learn more on considerations for choosing the right CDMO for your late-stage biotherapeutics programs in this interview with Stacey Treichler, Ph.D., Director, Head of Marketing & Strategy, BioModalities, Catalent Biologics.